Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Erasca is a clinical-stage, precision oncology company with a bold mission—to erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately 5.5 million new patients diagnosed globally per year.
Copyright © BetaNXT, Inc. or its affiliates. All rights reserved.